267 related articles for article (PubMed ID: 24897108)
41. Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach.
Venkatraman S; Balasubramanian B; Pongchaikul P; Tohtong R; Chutipongtanate S
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205315
[TBL] [Abstract][Full Text] [Related]
42. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing.
Yang W; Li Y; Song X; Xu J; Xie J
Oncotarget; 2017 Apr; 8(16):26591-26599. PubMed ID: 28427159
[TBL] [Abstract][Full Text] [Related]
43. Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma.
Lin P; Zhong XZ; Wang XD; Li JJ; Zhao RQ; He Y; Jiang YQ; Huang XW; Chen G; He Y; Yang H
Oncol Rep; 2018 Dec; 40(6):3189-3198. PubMed ID: 30272356
[TBL] [Abstract][Full Text] [Related]
44. The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations.
Feng Y; Zhao M; Wang L; Li L; Lei JH; Zhou J; Chen J; Wu Y; Miao K; Deng CX
Cell Death Dis; 2024 Jan; 15(1):34. PubMed ID: 38212325
[TBL] [Abstract][Full Text] [Related]
45. Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.
Huang C; Tian Y; Peng R; Zhang C; Wang D; Han S; Jiao C; Wang X; Zhang H; Wang Y; Li X
J Gastroenterol Hepatol; 2015 Feb; 30(2):421-33. PubMed ID: 25168293
[TBL] [Abstract][Full Text] [Related]
46. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
[TBL] [Abstract][Full Text] [Related]
47. Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.
Shimizu T; Yokomuro S; Mizuguchi Y; Kawahigashi Y; Arima Y; Taniai N; Mamada Y; Yoshida H; Akimaru K; Tajiri T
World J Gastroenterol; 2006 Oct; 12(39):6316-24. PubMed ID: 17072955
[TBL] [Abstract][Full Text] [Related]
48. Identification of hub genes and pathways in cholangiocarcinoma by coexpression analysis.
Kong J; Shen S; Zhang Z; Wang W
Cancer Biomark; 2020; 27(4):505-517. PubMed ID: 32116234
[TBL] [Abstract][Full Text] [Related]
49. Genetic profiling of intrahepatic cholangiocarcinoma.
Andersen JB; Thorgeirsson SS
Curr Opin Gastroenterol; 2012 May; 28(3):266-72. PubMed ID: 22395571
[TBL] [Abstract][Full Text] [Related]
50. Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma.
Sugimachi K; Nishio M; Aishima S; Kuroda Y; Iguchi T; Komatsu H; Hirata H; Sakimura S; Eguchi H; Bekki Y; Takenaka K; Maehara Y; Suzuki A; Mimori K
Oncology; 2017; 93(1):67-74. PubMed ID: 28448997
[TBL] [Abstract][Full Text] [Related]
51. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
[TBL] [Abstract][Full Text] [Related]
52. Notch1 Drives the Formation and Proliferation of Intrahepatic Cholangiocarcinoma.
Guo J; Fu W; Xiang M; Zhang Y; Zhou K; Xu CR; Li L; Kuang D; Ye F
Curr Med Sci; 2019 Dec; 39(6):929-937. PubMed ID: 31845224
[TBL] [Abstract][Full Text] [Related]
53. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma.
Wei M; Lü L; Lin P; Chen Z; Quan Z; Tang Z
Cancer Lett; 2016 Sep; 379(2):253-61. PubMed ID: 26940139
[TBL] [Abstract][Full Text] [Related]
54. Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma.
Zhong YJ; Luo XM; Liu F; He ZQ; Yang SQ; Ma WJ; Wang JK; Dai YS; Zou RQ; Hu YF; Lv TR; Li FY; Hu HJ
J Transl Med; 2024 May; 22(1):422. PubMed ID: 38702814
[TBL] [Abstract][Full Text] [Related]
55. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma.
Shen DY; Zhang W; Zeng X; Liu CQ
Cancer Sci; 2013 Oct; 104(10):1303-8. PubMed ID: 23822562
[TBL] [Abstract][Full Text] [Related]
57. Identifying the clonal origin of synchronous multifocal tumors in the hepatobiliary and pancreatic system using multi-omic platforms.
Jiang W; Ding Y; Shen Y; Fan L; Zhou L; Li Z; Zheng Y; Zhao P; Liu L; Tong Z; Fang W; Wang W
Oncotarget; 2017 Jan; 8(3):5016-5025. PubMed ID: 28008139
[TBL] [Abstract][Full Text] [Related]
58. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
Li J; Tian F; Li D; Chen J; Jiang P; Zheng S; Li X; Wang S
FEBS Lett; 2014 Sep; 588(18):3491-500. PubMed ID: 25131931
[TBL] [Abstract][Full Text] [Related]
59. Integration analysis of miRNA-mRNA expression exploring their potential roles in intrahepatic cholangiocarcinoma.
Liu L; Shi Y; Zhang P; Zhang X
Sci Rep; 2023 May; 13(1):8362. PubMed ID: 37225858
[TBL] [Abstract][Full Text] [Related]
60. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization.
Uhm KO; Park YN; Lee JY; Yoon DS; Park SH
Cancer Genet Cytogenet; 2005 Feb; 157(1):37-41. PubMed ID: 15676145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
